Ovation.io and PrecisionLife team to develop drug-response biomarkers for GLP-1 therapies
GLP-1 therapies are among the fastest-growing drug classes worldwide, projected to drive a $95 billion obesity market by 2030
GLP-1 therapies are among the fastest-growing drug classes worldwide, projected to drive a $95 billion obesity market by 2030
The clearance for TELLTALE positions Transmural Systems at the forefront of next-generation electrosurgical solutions for structural heart interventions
India's pharmaceutical sector is rapidly shifting from a generics-led foundation to an innovation-driven ecosystem
The drug, intended for chronic weight management alongside diet and exercise, is now under the FDA’s new CNPV expedited review pathway
The update reflects long-term clinical trial data showing that many patients with mCSCC or laCSCC experienced lasting responses
CD388 is administered as a single 450-milligram subcutaneous dose in adults and adolescents
It's a development that marks a major step forward for patients struggling with moderate-to-severe chronic spontaneous urticaria
The deal, backed by Gavi and executed by UNICEF, could generate up to US$90 million in savings—enough to provide more than 30 million additional doses
Subscribe To Our Newsletter & Stay Updated